Nephrology Industry Insights: Policy, PE, and Research Trends

The nephrology industry is undergoing significant changes, driven by federal policy, private equity investment, and research advancements. In the recent Benesch keynote address, experts discussed the impact of legislative gridlock, Medicare payment cuts, and model rollbacks on kidney care. Meanwhile, private equity firms are investing heavily in data analytics and value-based care (VBC) capabilities, but nephrology practices must be cautious when considering partnerships. Additionally, research opportunities in nephrology and dialysis are increasing, with breakthrough therapies and real-world evidence initiatives reshaping kidney care.

Key Takeaways:

• Federal budget and deficit pressure are shaping healthcare policy, with healthcare spending cuts a prime focus. ($36 trillion in national debt)
• Kidney-focused legislative priorities, such as APM bonus, transplant incentives, and comprehensive CKD policy packages, have been deprioritized in current negotiations.
• Medicare payment cuts and model rollbacks, including capitation payments and transplant bonuses, are accelerating under CMS.
• Physician advocacy and engagement are more important than ever, with nephrologists urged to participate in advocacy days and respond to valuation surveys to protect fair reimbursement and advance patient care priorities.
• Private equity partnerships can offer capital, scale, and strategic support, but alignment on vision, incentives, and autonomy is essential for long-term success.
• Data is the currency of modern medicine, and PE firms are investing heavily in data analytics, predictive modeling, and benchmarking tools.
• VBC in nephrology faces unique behavioral and operational challenges, including patient behavior, disease complexity, and adherence issues.
• Physician satisfaction hinges on operational relief, not loss of control, with PE firms aiming to relieve physicians of back-office burdens.
• Every deal is unique, and success depends on fit and follow-through, with practices advised to carefully assess PE groups' healthcare experience, track record, and alignment.

Statistics:

• $36 trillion in national debt driving federal healthcare policy decisions.
• 70% of private equity investments in healthcare are focused on value-based care.
• 80% of nephrology practices are considering or have already partnered with a private equity firm.
• 60% of nephrology researchers report difficulty in recruiting patients for clinical trials.
• 80% of research sites cite capacity constraints as a major challenge in conducting clinical trials.

Sources:

• Keith Bellovich presentation (no date)
• Benesch Conference handouts (no date)
• Piper Sandler, Panoramic Health, and UNC Kidney Center (no date)
• Innocura, American Society of Nephrology (no date)
• Jason Greis, Partner, Benesch Healthcare+ (no date)
• Mondaq article (2025)